Bioavailability Enhancing and Incretin Inducing Nanostructured Lipid Carriers for Diabetes: An In Vivo Evaluation

Lay-Hong Chuah – Associate Professor, Monash University; Chee Wun How – Senior Lecturer, Monash University Malaysia; Rajesh Sreedharan Nair – Associate Professor, University of Nottingham Malaysia

Introduction:

Existing incretin-based therapies employ either receptor-targeting analogues or inhibition of incretin hormone degradation via dipeptidyl peptidase-4 (DPP-4) [1]. Linagliptin, with a bioavailability of approximately 30% adopts the latter strategy and produces only a modest increase in glucagon-like peptide-1 (GLP-1), an endogenous incretin hormone, compared with receptor-targeting approaches [2-3]. Therefore, this study aims to evaluate the preclinical pharmacokinetic profiles and glucose-lowering efficacy of Linagliptin-loaded nanostructured lipid carriers (LG-NLC) designed to enhance bioavailability and stimulate GLP-1 secretion.